Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed. The full letter is embedded ... Read More The post Advocating for Patients: Letter to the FDA on RP1 Treatment Access appeared first on AIM...
